The clinical benefits of hormonal treatment for LG-ESS: a meta-analysis
- 55 Downloads
To evaluate the clinical benefits of hormonal treatment for patients with low-grade endometrial stromal sarcoma (LG-ESS) by reviewing the published literature and performing a meta-analysis.
Correlational studies related to hormonal treatment for LG-ESS patients were collected by searching the PubMed, EMBASE, and Cochrane databases up to December 2018. Eligible studies were selected based on inclusion and exclusion criteria. The main inclusion criteria included: original studies with definite diagnoses of LG-ESS that evaluated the clinical benefits of hormonal treatment, studies with at least 10 cases, and studies published in English. Reviews, case reports, letters, comments or conference abstracts, studies without sufficient data and overlapping or republished studies were excluded. The study quality was evaluated, and pooled relative risks and 95% confidence intervals were calculated using Review Manager 5.3.
A total of 10 retrospective studies were included. The NOS stars of the 10 studies ranged from 7 to 9 points, which was considered to be of high quality. Recurrence and death information was provided in 9 and 6 studies, respectively. The overall pooled RR for recurrence was 0.66 (95% CI 0.47–0.94), which indicated that hormonal treatment was effective at reducing the recurrence risk (P = 0.02). The overall pooled RR for death was 0.81 (95% CI 0.59–1.12), which showed that hormonal treatment had little effect in prolonging overall survival (P = 0.20). Stratified analysis showed that compared with the group without any adjuvant treatments, hormonal treatment alone significantly decreased the risk of recurrence (P = 0.02), while hormonal treatment had no significant effects on overall survival (P = 0.38). Another subgroup analysis indicated that for stage I–II patients, hormonal treatment could significantly decrease the risk of recurrence (P = 0.02) but could not influence overall survival (P = 0.87). However, for stage III–IV patients, hormonal treatment had little benefit both in reducing the recurrence risk and prolonging overall survival (P = 0.49/0.08). Egger’s and Begg’s test showed that the publication bias for the literature was satisfactorily controlled.
Adjuvant hormonal treatment should be considered as a feasible adjuvant therapy for reducing the recurrence risk of patients with LG-ESS while bearing little benefit on overall survival.
KeywordsAdjuvant hormonal treatment Low-grade endometrial stromal sarcoma Recurrence Overall survival Meta-analysis
The present study is contributed by Ran Cui, Guangming Cao, Huimin Bai, and Zhenyu Zhang. RC: data collection and analysis, manuscript writing; GMC: data collection and analysis, HMB and ZYZ: protocol development, data management and analysis, and manuscript editing.
This work was supported by the Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding-YangFan Project (No.ZYLX201713) and National Natural Science Foundation of China (No. 81972424).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 3.Yamazaki H, Todo Y, Mitsube K, Hareyama H, Shimada C, Kato H, Yamashiro K (2015) Long-term survival of patients with recurrent endometrial stromal sarcoma: a multicenter, observational study. J Gynecol Oncol 26(3):214–221. https://doi.org/10.3802/jgo.2015.26.3.214 CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Yoon A, Park JY, Park JY, Lee YY, Kim TJ, Choi CH, Bae DS, Kim BG, Lee JW, Nam JH (2014) Prognostic factors and outcomes in endometrial stromal sarcoma with the 2009 FIGO staging system: a multicenter review of 114 cases. Gynecol Oncol 132(1):70–75. https://doi.org/10.1016/j.ygyno.2013.10.029 CrossRefPubMedGoogle Scholar
- 10.Amant F, De Knijf A, Van Calster B, Leunen K, Neven P, Berteloot P, Vergote I, Van Huffel S, Moerman P (2007) Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma. Br J Cancer 97(9):1194–1199. https://doi.org/10.1038/sj.bjc.6603986 CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Deshmukh U, Black J, Perez-Irizarry J, Passarelli R, Levy K, Rostkowski A, Hui P, Rutherford TJ, Santin AD, Azodi M, Silasi DA, Ratner E, Litkouhi B, Schwartz PE (2018) adjuvant hormonal therapy for low-grade endometrial stromal sarcoma. Reprod Sci 193:01. https://doi.org/10.1177/1933719118778801 CrossRefGoogle Scholar
- 14.Zhou J, Zheng H, Wu SG, He ZY, Li FY, Su GQ, Sun JY (2015) Influence of different treatment modalities on survival of patients with low-grade endometrial stromal sarcoma: a retrospective cohort study. Int J Surg Lond Engl 23(Pt A):147–151. https://doi.org/10.1016/j.ijsu.2015.09.072 CrossRefGoogle Scholar
- 20.Bai H, Yang J, Cao D, Huang H, Xiang Y, Wu M, Cui Q, Chen J, Lang J, Shen K (2014) Ovary and uterus-sparing procedures for low-grade endometrial stromal sarcoma: a retrospective study of 153 cases. Gynecol Oncol 132(3):654–660. https://doi.org/10.1016/j.ygyno.2013.12.032 CrossRefPubMedGoogle Scholar
- 22.Ali RHA-Ohoo, Rouzbahman M Endometrial stromal tumours revisited: an update based on the 2014 WHO classification. (1472–4146 (Electronic)) Google Scholar
- 23.Amant F, Floquet A, Friedlander M, Kristensen G, Mahner S, Nam EJ, Powell MA, Ray-Coquard I, Siddiqui N, Sykes P, Westermann AM, Seddon B (2014) Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma. Int J Gynecol Cancer 24(9):S67–S72. https://doi.org/10.1097/IGC.0000000000000205 CrossRefPubMedGoogle Scholar